Show table of contents · 10 sections▾
This is a plain-English explainer, not legal advice. Only a licensed attorney representing you can evaluate the specific facts of your case.
The Philips CPAP Litigation at a Glance
In June 2021, Philips Respironics recalled approximately 15 million CPAP, BiPAP, and mechanical ventilator devices due to concerns that the polyester-based polyurethane (PE-PUR) sound abatement foam degrades over time. Degraded foam particles and off-gassed chemicals can be inhaled by users. Plaintiffs allege the exposure caused cancers, respiratory illnesses, and other conditions.
MDL 3014 Formation and Status
The JPML consolidated federal Philips CPAP cases in MDL 3014 in the Western District of Pennsylvania before Judge Joy Flowers Conti in October 2021. Two case tracks emerged:
- Economic loss track: Device replacement, refund, and medical monitoring claims.
- Personal injury track: Individual claims for cancer, respiratory illness, and other injuries.
Economic Loss Settlement (October 2024)
Philips agreed to a $1.1 billion global settlement covering economic loss claims. Registered users of recalled devices are eligible for benefits including device replacement, refund, or opt-out for individual personal injury claim continuation.
Personal Injury Cases Continue Separately
Individual personal injury claims for cancer and respiratory illness are not covered by the economic loss settlement. These proceed as individual cases within MDL 3014's personal injury track. Bellwether trials expected 2026–2027.
Alleged Injuries
- Lung cancer.
- Kidney cancer.
- Liver cancer.
- Bladder cancer.
- Other cancers with plausible exposure link.
- Respiratory illnesses (COPD exacerbation, chronic bronchitis).
- Acute inhalation injury.
Recalled Devices
The recall covered many Philips DreamStation, System One, and other CPAP/BiPAP models manufactured between 2009 and April 26, 2021. Ventilator models (Trilogy 100, Trilogy 200) also included. Full recall list on FDA and Philips websites.
Documentation for a Personal Injury Case
- Confirmed use of recalled Philips device.
- Duration and frequency of device use.
- Cancer diagnosis or documented respiratory injury.
- Medical records establishing timeline consistent with device exposure.
Funding Availability
Pre-settlement funding is available for filed personal injury cases with documented device use, injury diagnosis, and represented counsel in MDL 3014.
The Bottom Line
The Philips CPAP litigation has already produced a significant economic loss settlement. Personal injury cases involving cancer and respiratory injury continue as individual cases with pre-settlement funding available. If you used a recalled Philips device and developed cancer or respiratory illness, consult an MDL 3014 attorney.
At Instabridge Funding, we work with plaintiff attorneys across all fifty states — attorney-founded, non-recourse, and transparently priced. If your case is filed and you would like a fair pre-settlement offer, apply through our portal and your attorney will hear back within one business day.
Frequently asked questions
Approximately 15 million CPAP, BiPAP, and mechanical ventilator devices manufactured by Philips Respironics between 2009 and April 2021, due to foam degradation risk.
A global economic loss settlement covering device replacement, refund, and medical monitoring for registered users. Announced October 2024.
No. Personal injury cases (cancer, respiratory injury) proceed separately within MDL 3014's personal injury track.
Lung, kidney, liver, and bladder cancers with plausible exposure link, plus chronic and acute respiratory illnesses documented after device use.
Registration for economic loss benefits typically does not waive personal injury claims — but confirm with your attorney. Some settlements have opt-out provisions.
Check the Philips recall website or FDA recall database using your device's serial number.
Yes, for filed personal injury cases with documented device use, cancer or respiratory injury diagnosis, and represented counsel.
Bellwether trials expected 2026–2027 with global settlement negotiations potentially following 2027–2029.
